Overexpression of Potential Markers of Regulatory and Exhausted CD8
Child
Humans
CD8-Positive T-Lymphocytes
/ metabolism
Interleukin-10
/ metabolism
CTLA-4 Antigen
/ metabolism
Hepatitis A Virus Cellular Receptor 2
/ metabolism
Receptors, Tumor Necrosis Factor, Type II
/ metabolism
Leukocytes, Mononuclear
/ metabolism
Ki-67 Antigen
/ metabolism
T-Lymphocytes, Regulatory
/ metabolism
Transforming Growth Factor beta
/ metabolism
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/ metabolism
Acute Disease
Forkhead Transcription Factors
/ genetics
B-acute lymphoblastic leukemia
CD8 exhaustion markers
Treg markers
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Feb 2023
24 Feb 2023
Historique:
received:
09
02
2023
revised:
20
02
2023
accepted:
21
02
2023
entrez:
11
3
2023
pubmed:
12
3
2023
medline:
15
3
2023
Statut:
epublish
Résumé
B-acute lymphoblastic leukemia (B-ALL) is one of the most common pediatric cancers, wherein regulatory T cells (Treg) and exhausted CD8
Identifiants
pubmed: 36901957
pii: ijms24054526
doi: 10.3390/ijms24054526
pmc: PMC10003658
pii:
doi:
Substances chimiques
Interleukin-10
130068-27-8
CTLA-4 Antigen
0
Hepatitis A Virus Cellular Receptor 2
0
Receptors, Tumor Necrosis Factor, Type II
0
Ki-67 Antigen
0
Transforming Growth Factor beta
0
Forkhead Transcription Factors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Italian Ministry of Universities and Research
ID : PRIN 2017B9NCSX
Références
Hematology. 2015 Oct;20(9):523-9
pubmed: 26119924
Nucleic Acids Res. 2002 Jan 1;30(1):207-10
pubmed: 11752295
Front Immunol. 2019 Oct 04;10:2301
pubmed: 31636635
Front Immunol. 2020 Oct 08;11:574271
pubmed: 33162990
Proc Natl Acad Sci U S A. 2020 Jun 23;117(25):14331-14341
pubmed: 32513686
Int J Mol Sci. 2019 Oct 22;20(20):
pubmed: 31652661
Oncoimmunology. 2016 Mar 10;5(6):e1150398
pubmed: 27471618
Immunology. 2014 May;142(1):124-39
pubmed: 24354800
Cytokine. 2018 Jan;101:14-18
pubmed: 27531077
Int J Oncol. 2015 Dec;47(6):2082-90
pubmed: 26460798
Eur J Immunol. 2016 Jun;46(6):1438-48
pubmed: 26990545
Proc Natl Acad Sci U S A. 2008 Feb 26;105(8):3005-10
pubmed: 18287062
Leukemia. 2022 Mar;36(3):790-800
pubmed: 34584204
Science. 2003 Feb 14;299(5609):1057-61
pubmed: 12522256
Oncogene. 2019 Mar;38(13):2420-2431
pubmed: 30532071
J Exp Med. 2006 Jul 10;203(7):1693-700
pubmed: 16818676
Immunity. 2009 May;30(5):626-35
pubmed: 19464985
Blood Adv. 2022 Sep 27;6(18):5440-5448
pubmed: 35759759
Cell Res. 2017 Jan;27(1):109-118
pubmed: 27995907
Front Immunol. 2021 Jul 20;12:715234
pubmed: 34354714
Oncol Lett. 2016 Nov;12(5):4080-4086
pubmed: 27895775
Exp Ther Med. 2018 Aug;16(2):1433-1441
pubmed: 30116392
Eur J Immunol. 2022 Aug;52(8):1216-1227
pubmed: 35879813
Cancer Lett. 2020 Oct 10;490:174-185
pubmed: 32721551
Dis Markers. 2021 Jun 22;2021:5574472
pubmed: 34257746
Nat Rev Cancer. 2001 Dec;1(3):245-50
pubmed: 11902580
Nucleic Acids Res. 2015 Jan;43(Database issue):D1113-6
pubmed: 25361974
J Immunol Res. 2017;2017:1832968
pubmed: 29430466
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2010 Jun;18(3):709-13
pubmed: 20561434
Blood Cells Mol Dis. 2009 Mar-Apr;42(2):117-20
pubmed: 19064328
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
Immunotargets Ther. 2021 Apr 21;10:103-122
pubmed: 33907692
Cancer Immunol Immunother. 2022 Mar;71(3):579-588
pubmed: 34278517
J Cell Physiol. 2015 Nov;230(11):2598-605
pubmed: 25913194
Int J Mol Sci. 2021 Jul 28;22(15):
pubmed: 34360833
Cell Immunol. 2019 Oct;344:103958
pubmed: 31376919
J Cell Mol Med. 2022 Aug;26(16):4566-4576
pubmed: 35822529
Cancer Discov. 2015 Dec;5(12):1244-6
pubmed: 26637659
Front Immunol. 2021 Feb 02;11:622509
pubmed: 33633741
Science. 2015 Oct 16;350(6258):334-9
pubmed: 26472910
Leukemia. 2022 Feb;36(2):403-415
pubmed: 34381181
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Aug;24(4):1264-8
pubmed: 27531813
Oncoimmunology. 2017 Nov 9;7(2):e1387705
pubmed: 29308313
Cancers (Basel). 2022 May 25;14(11):
pubmed: 35681583
J Immunol. 1995 Aug 1;155(3):1151-64
pubmed: 7636184
J Clin Invest. 2007 May;117(5):1137-46
pubmed: 17476343
Leuk Res. 2018 Apr;67:60-66
pubmed: 29455107
J Exp Med. 2006 Jul 10;203(7):1701-11
pubmed: 16818678
Leuk Res. 2010 Feb;34(2):173-6
pubmed: 19679351
Cancer Lett. 2020 Jan 28;469:151-161
pubmed: 31669202
Immunology. 2012 Apr;135(4):255-60
pubmed: 22112044
J Immunol. 2010 Apr 1;184(7):3433-41
pubmed: 20181882
Leukemia. 2021 Sep;35(9):2602-2615
pubmed: 33597728
Cancer Res. 2018 Jan 1;78(1):115-128
pubmed: 29066514
Oncotarget. 2018 Dec 11;9(97):36993-37007
pubmed: 30651930
Int Immunopharmacol. 2022 Mar;104:108469
pubmed: 35008005
Biomed Res Int. 2020 Jul 27;2020:4612952
pubmed: 32802845
Front Immunol. 2015 Aug 03;6:395
pubmed: 26284077
Sci Rep. 2021 Jul 22;11(1):15039
pubmed: 34294814
PLoS Pathog. 2015 Oct 20;11(10):e1005177
pubmed: 26485519
Immunology. 2023 Jan;168(1):30-48
pubmed: 36190809
Semin Immunopathol. 2019 May;41(3):327-337
pubmed: 30989321
J Hematol Oncol. 2020 Aug 12;13(1):111
pubmed: 32787882